Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutationdiversity, ductility, and destiny

Medicine and Dentistry

• Epidermal Growth Factor Receptor Kinase Inhibitor 58%
• Epidermal Growth Factor Receptor 41%
• Lung Cancer 33%
• Hepatocyte Growth Factor 25%
• In Vitro 16%
• Cell Line 16%
• Patient 8%
• Gene 8%
• Development 8%
• Drug 8%
• Inpatient 8%
• Chemotherapeutic Agent 8%
• Cancer Cell 8%
• Diseases 8%
• Exercise 8%
• Comprehension 8%
• Survival 8%
• Mesenchymal-Epithelial Transition 8%
• Somatics 8%
• Mutant 8%
• down Regulation 8%
• Small Cell Lung Cancer 8%
• Patient with Cancer 8%
• Molecular Marker 8%
• Tyrosine-Kinase Inhibitor 8%
• Chronic Disorder 8%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Receptor Tyrosine Kinase Inhibitors 58%
• Mutation 33%
• Sample 8%
• Nested Gene 8%
• Development 8%
• Electric Potential 8%
• Cancer Cell 8%
• Comprehension 8%
• Exercise 8%
• Mutant 8%
• down Regulation 8%
• Survival 8%
• Mesenchymal-Epithelial Transition 8%
• Genetic Marker 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor Kinase Inhibitor 58%
• Epidermal Growth Factor Receptor 41%
• Lung Cancer 33%
• Drug 8%
• Diseases 8%
• Survival 8%
• Small Cell Lung Cancer 8%
• Protein Tyrosine Kinase Inhibitor 8%
• Molecular Marker 8%
• Molecular Target 8%